E. A. de Bruijn - Concepedia

Author

E. A. de Bruijn

Also Known As

E A De Bruijn, E A de Bruijn, E. A de Bruijn, E. A. DE BRUIJN, E. A. De Bruijn, E. A. de Bruijn, E.A de Bruijn, E.A. De Bruijn, E.A. De Bruijn ., E.A. De Bruijn∗

163

Publications

6.1K

Citations

H-Index

114

Concepts

All Affiliations

KU Leuven University of Antwerp Leiden University Utrecht University Rotterdam University of Applied Sciences

About

E. A. de Bruijn is an author at KU Leuven specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	56	2K
2	Health Sciences	8	8	268
3	Natural Sciences	4	4	73
4	Engineering	3	3	76
5	Anesthesia	1	1	11

E. A. de Bruijn

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11 Hans Wildiers, G. Guetens, Gert De Boeck, British Journal of Cancer	2003	328
Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer Paul H. Sugarbaker, W.J. Cunliffe, J. Belliveau, Surgical OncologyGastrointestinal OncologySurgical TreatmentMedicineGastroenterology	1991	233
Interaction of Imatinib with Human Organic Ion Carriers Shuiying Hu, Ryan M. Franke, Kelly K. Filipski, Clinical Cancer Research	2008	228
Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion Johannes H. W. de Wilt, Timo L.M. ten Hagen, Gert De Boeck, British Journal of Cancer	2000	204
Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps Herman Burger, Hans van Tol, Mariël Brok, Cancer Biology & Therapy Cancer ResearchOncologyDrug Transport PumpsTumor MicroenvironmentImatinib Mesylate	2005	204
Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo? Wim Wynendaele, Rita Derua, Marc Hoylaerts, Annals of Oncology ThrombopoiesisThrombosisAngiogenesisHealth SciencesCardiovascular Disease	1999	114
Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas P. Vermeulen, Didier Verhoeven, Guy Hubens, Annals of Oncology Microvessel DensityMedicineBiological MicroenvironmentsColorectal CancerPathology	1995	104
Development of a Rapid and Sensitive Method for the Quantitation of Amphetamines in Human Plasma and Oral Fluid by LC-MS-MS Michelle Wood, Gert De Boeck, Nele Samyn, Journal of Analytical Toxicology Forensic ChemistryDrug PurityBioanalysisDrug TestAnalytical Chemistry	2003	84
cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Peter J.K. Kuppen, Hanneke Schuitemaker, Laura van ‘t Veer, PubMed Cddp ConcentrationMedicinePharmacologyGynecologyCell Lines	1988	76
Suramin for prostatic cancer: A phase I/II study in advanced extensively pretreated disease Allan T. van Oosterom, Eric A. De Smedt, Louis Denis, European Journal of Cancer and Clinical Oncology Pretreated DiseaseUrologyProstatic CancerPhase I/ii StudyMedicine	1990	57

Page 1